MCRB Stock Overview
A clinical-stage company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Seres Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.63 |
| 52 Week High | US$30.60 |
| 52 Week Low | US$7.18 |
| Beta | 2.53 |
| 1 Month Change | -24.77% |
| 3 Month Change | -42.04% |
| 1 Year Change | -58.49% |
| 3 Year Change | -88.11% |
| 5 Year Change | -89.53% |
| Change since IPO | -99.06% |
Recent News & Updates
Recent updates
Little Excitement Around Seres Therapeutics, Inc.'s (NASDAQ:MCRB) Revenues As Shares Take 30% Pounding
Nov 15
Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade
Sep 23Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 44% But Investors Aren't Buying For Growth
Jul 13Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 46% But Investors Aren't Buying For Growth
May 08Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet
Mar 23Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns
Jan 30Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop
Dec 18Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop
Aug 31Seres Therapeutics (NASDAQ:MCRB) Has Debt But No Earnings; Should You Worry?
Aug 09Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?
Dec 28Estimating The Fair Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)
Sep 01Seres Therapeutics: What The Market Is Missing
Aug 19Seres Therapeutics GAAP EPS of -$0.70 misses by $0.10, revenue of $1.22M
Aug 03Seres Therapeutics: The Good And The Challenging
Jul 12Seres Therapeutics stock slips on $100M stock offering
Jun 30Is Seres Therapeutics (NASDAQ:MCRB) Using Too Much Debt?
Jun 16Shareholder Returns
| MCRB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.5% | 2.8% | 3.0% |
| 1Y | -58.5% | -6.8% | 10.1% |
Return vs Industry: MCRB underperformed the US Biotechs industry which returned -6.7% over the past year.
Return vs Market: MCRB underperformed the US Market which returned 10% over the past year.
Price Volatility
| MCRB volatility | |
|---|---|
| MCRB Average Weekly Movement | 16.0% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: MCRB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MCRB's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 103 | Eric Shaff | www.serestherapeutics.com |
Seres Therapeutics, Inc., a clinical-stage company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. The company develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company’s product candidate is VOWST, the first FDA-approved orally administered microbiome therapeutic.
Seres Therapeutics, Inc. Fundamentals Summary
| MCRB fundamental statistics | |
|---|---|
| Market cap | US$83.95m |
| Earnings (TTM) | -US$125.77m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs MCRB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MCRB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$14.53m |
| Gross Profit | -US$14.53m |
| Other Expenses | US$111.24m |
| Earnings | -US$125.77m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 07, 2025
| Earnings per share (EPS) | -14.43 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MCRB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/04 03:15 |
| End of Day Share Price | 2025/05/02 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Seres Therapeutics, Inc. is covered by 19 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| John Newman | Canaccord Genuity |
| John Tanner | Cantor Fitzgerald & Co. |